SciELO - Scientific Electronic Library Online

 
vol.58 número3Physical activity as a predictor of absence of frailty in the elderlySpontaneous pneumomediastinum: case report índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista da Associação Médica Brasileira

versión impresa ISSN 0104-4230

Rev. Assoc. Med. Bras. vol.58 no.3 São Paulo mayo/un. 2012

http://dx.doi.org/10.1590/S0104-42302012000300016 

ORIGINAL ARTICLE

 

Cardiovascular risk in patients submitted to liver transplantation

 

 

Hélem de Sena RibeiroI; Lucilene Rezende AnastácioII; Lívia Garcia FerreiraIII; Agnaldo Soares LimaIV; Maria Isabel Toulson Davisson CorreiaV

INutritionist, Universidade Federal de Minas Gerais (UFMG); MSc Student in Foods Sciences, UFMG, Belo Horizonte, MG, Brazil
IIMSc in Foods Sciences, UFMG; PhD Student in Adult Health-Applied Sciences; Professor at Centro Universitário de Sete Lagoas, Sete Lagoas, MG, Brazil
IIIMSc in Food Sciences, UFMG; PhD Student in Ophthalmology and Surgery Applied Sciences; Professor at Universidade de Itaúna, Itaúna, MG, Brazil
IVPhD in Gastroenterology, UFMG; Adjunct Professor, UFMG, Belo Horizonte, MG, Brazil
VPost-doctorate, University of Pittsburgh Medical Center; Full Professor of Surgery, UFMG, Belo Horizonte, MG, Brazil

Correspondence to

 

 


SUMMARY

OBJECTIVE: To determine the prevalence of cardiovascular risk in patients undergoing liver transplantation according to the Framingham score, and to evaluate possible associations with traditional and non-traditional risk factors.
METHODS: Cross-sectional study in which patients undergoing liver transplantation were stratified by cardiovascular risk according to the Framingham score. Demographic, socioeconomic, clinical, and anthropometric variables were collected to assess the association with cardiovascular risk factors using univariate and multivariate statistical analyses.
RESULTS: A total of 115 patients were evaluated, of which 46.1% showed medium or high risk for the occurrence of cardiovascular events over ten years. The mean percentage risk of evaluated patients was of 9.5 ± 7.8%. Male gender (OR: 4.97; CI: 1.92-12.85; p < 0.01), older age (OR: 1,09; CI: 1.04-1.13; p < 0.01), and higher BMI at the moment of assessment (1.09; CI: 0.99-1.20; p = 0.03) were factors associated with medium and high cardiovascular risk. A higher percentage of cardiovascular risk was also associated with cyclosporine use (p = 0.01).
CONCLUSION: The probability of occurrence of cardiovascular events in the assessed patients undergoing liver transplantation was higher than that in the Brazilian population. Special attention should be paid to this population, especially in relation to potentially modifiable factors associated to higher BMI and cyclosporine use.

Keywords: risk factors; cardiovascular diseases; liver transplant.


 

 

INTRODUCTION

Liver transplantation is the treatment of choice for patients with irreversible acute or chronic liver failure. The combination of advances in surgical technique, patient selection, better perioperative care, and adequate availability of immunosuppressive agents has resulted in significant improvement in the overall survival aftertransplantation1. Currently, almost 90% of patients survive one year after the transplantation2, and up to 75% survive after 5 years3.

However, the increased survival of patients undergoing liver transplantation has been accompanied by increased prevalence of chronic diseases, usually higher than that found in the general population4. Obesity, diabetes mellitus, arterial hypertension, dyslipidemia and metabolic syndrome are widely diagnosed in these patients5-6; consequently, the incidence of cardiovascular disease has also been increasingly described in this population7. Cardiovascular disease has been identified as the third leading cause of death after liver transplantation8. Some authors demonstrated that the risk of ischemic cardiac events and cardiovascular death are respectively 3.07 and 2.56 times higher in recipients of liver graft compared to age-matched population not submitted to transplantation9.

The immunosuppressive agents used in the posttransplantation (usually tacrolimus or cyclosporine, and prednisone - at least in the early stages), although broadly described as responsible for the increase in cardiovascular risk10, have not always shown that association9,11. While much attention has been devoted to the study of immunosuppressive drugs associated with chronic diseases such as those present in these patients, few risk factors, except these, have been studied, and to date, the cardiovascular risk in the Brazilian population referred for liver transplantation is still unknown.

The present study aimed to determine the prevalence of cardiovascular risk in patients undergoing liver transplantation according to the Framingham score, and to evaluate possible associations with other variables not included in this score.

 

METHODS

This is a cross-sectional study in which cardiovascular risk according to Framingham score was evaluated in patients undergoing liver transplantation followed at the outpatient clinic of transplantation of the Instituto Alfa de Gastroenterologia, Hospital das Clínicas, Universidade Federal of Minas Gerais (Belo Horizonte - MG). Data were collected from March to October 2008. Patients who underwent liver transplantation and were at least 18 years of age were included in the study. Pregnant women and patients with ascites were excluded from the sample, as these conditions would hinder the identification of patients with abdominal obesity. Likewise, patients with time of transplantation of less than one year were not included, as they often have new and transient metabolic disorders as a result of graft implantation and high doses of immunosuppressants. The study was approved by the Ethics Committee of the Universidade Federal de Minas Gerais under protocol No. ETIC 44/08.

The patients were approached and asked about their interest in participating in the study while waiting for medical consultation at the clinic. After signing the informed consent, a questionnaire was applied covering demographic, socioeconomic, lifestyle, clinical and anthropometric data.

Demographic and socioeconomic data included age, gender, marital status, paid professional activity, education, and income. Variables related to lifestyle consisted of usual hours of sleep per night, smoking and former smoking status, and physical activity level.

Patients were asked about daily physical activities and the corresponding responses were transformed into metabolic equivalent tasks (METs)12. The daily activities transformed in METs were multiplied by the respective time spent, expressed as fractions of the hour; the results were summed and then divided by 24 hours. This value was categorized according to the level of activity performed (< 1.3: sedentary, 1.3 to 1.5: little active, 1.5 to 1.8: active, > 1.9: very active)13 .

Clinical data included indication for transplantation; time of use and cumulative dose of corticosteroids after transplantation; use of tacrolimus or cyclosporine; hypertension prior to transplantation and at the time of the interview; diabetes mellitus prior to transplantation and at the time of the interview; excess weight and obesity prior to liver disease (based on the weight reported by the patient during the interview); family history of hypertension, diabetes mellitus, overweight, and cardiovascular disease.

Anthropometric data consisted of weight, height, body mass index (BMI), waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR). BMI was calculated by dividing weight (kg) by height squared (m2), and patients were classified as overweight (BMI > 25 kg/m2) or obese (BMI > 30 kg/m2)14. The WC measurement (two fingers above the umbilicus) was classified as indicative of abdominal obesity according to the definitions of the World Health Organization (> 88 cm for women and > 102 cm for men)14 and of the International Diabetes Federation (IDF) (> 80 cm and > 90 cm, respectively)15.

The Framingham risk score was calculated and stratified according to gender, age, total cholesterol (TC), high density lipoprotein (HDL), smoking, systolic blood pressure (SBP), and diastolic blood pressure (DBP).

Patients were classified into groups according to cardiovascular risk consistent with the obtained score (< 10%, low risk, 10% to 20%, medium risk, > 20%, high risk), and by clinical manifestations of atherosclerotic disease or equivalent, such as the presence of diabetes mellitus type 1 or type 2 (such individuals show risk > 20% of new cardiovascular events over 10 years)16.

Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) for Windows (version 17.0), adopting a statistical significance level of 5%. The variables are shown as mean and standard deviation, and variables with non-normal distribution are shown as median, minimum, and maximum values (Kolmogorov- Smirnov test).

Patients with medium (10%-20%) and high risk (> 20%) were grouped and compared to low risk patients (< 10%) in the statistical analysis, as the medium-risk group had a small numbers of patients. Factors associated with medium/high cardiovascular risk were tested by univariate and multivariate analyses. The statistical tests used in univariate analysis were the chi-square test, Fisher's exact test, Student's t-test, and the Mann-Whitney test. Variables with p < 0.2 in the univariate analysis were included in the multiple logistic regression model. The model was subsequently adjusted according to the stepwise backward method. The Hosmer and Lemeshow test was used to check the fit of the model (p > 0.05). Also, multiple linear regression was used to identify factors associated with a higher percentage of cardiovascular risk.

 

RESULTS

The sample comprised 115 subjects, of which 58.2% were males (n = 67). The mean age at evaluation was 52.5 ± 13.1 years. The average time of transplantation was 56.8 ± 34.7 months. Regarding schooling, the plurality of the individuals had not graduated from college/university (39.1%, n = 45), high school (26.1%, n = 30), and elementary school (26.1%, n = 30). Furthermore, 11.3% (n = 13) of the evaluated individuals reported to be illiterate. The general characterization of the patients is described in Table 1.

The most frequent indications for transplantation were alcoholic cirrhosis (31.3%, n = 36), cirrhosis due to hepatitis C virus (27.8%, n = 32), cirrhosis due to autoimmune hepatitis (14.8%, n = 17), cryptogenic cirrhosis (n = 14 12.2%), and cirrhosis with hepatocellular carcinoma (7%, n = 8). Other indications were observed in 20.9% (n = 24) of cases.

Family history of hypertension, diabetes mellitus, obesity, and cardiovascular disease were reported by 74.3% (n = 84), 49.6% (n = 56), 64.6% (n = 73) and 61.1% (n = 59) of patients, respectively. Personal history of overweight prior to liver disease was observed in 42.6% (n = 49) of patients and obesity, in 13.9% (n = 16). At the time of evaluation, the prevalence of overweight was 58.2% (n = 96) and of obesity, 20.9% (n = 24) of patients. Abdominal obesity was observed in 44.3% (n = 51) patients according to the WHO classification, and in 71.1% (n = 82) according to the IDF classification.

According to the Framingham risk score, 53.9% (n = 62) patients had low risk for cardiovascular events over ten years and 46.1% (n = 53) had medium to high risk, of which 16.5% (n = 19) of patients were classified as medium and 29.6% (n = 34) as high risk for cardiovascular events in ten years. The mean percentage risk was 9.5% ± 7.8%. Male gender, older age, indication for transplantation due to alcoholic cirrhosis, overweight, obesity, higher BMI prior to liver disease, higher BMI, WC, and WHR at the time of assessment were statistically associated, in the univariate analysis, to a probability higher than 10% of coronary events occurring within ten years for these patients (Tables 2 and 3).

Factors that are directly or indirectly associated with the calculation of the Framingham score were also associated with risk in the univariate analysis (glucose, total cholesterol, HDL, and triglycerides), but were not included in the multiple or linear logistic regression models.

The multiple logistic regression model created to identify factors independently associated with medium and high cardiovascular risk showed a good fit (Hosmer and Lemeshow test = 0.88) and resulted in the following variables: age (OR: 1.09 CI: 1.04-1.13, p < 0.01), male (OR: 4.97 CI: 1.92-12.85, p < 0.01), and BMI at the time of evaluation (OR: 1.09, CI: 0.99-1.20, p = 0.09). Variables independently associated with a higher percentage of cardiovascular risk through the multiple linear regression model were age (p < 0.01), male sex (p < 0.01), cyclosporine use (p = 0.01), and higher body mass index at evaluation (p = 0.03).

 

DISCUSSION

The Framingham risk score was used in this study as it is recommended by the Brazilian Society of Cardiology16 and is the standard most often used for stratification of coronary risk worldwide. The estimated risk of cardiovascular disease in asymptomatic individuals and the identification of associated factors may be useful to classify vulnerable groups and allow the development of strategies to prevent these problems. However, it is important to emphasize that this algorithm has limitations, as it only considers traditional risk factors: age, total cholesterol, systolic and diastolic blood pressure, diabetes mellitus and smoking status.

Other important risk factors in the epidemiology of cardiovascular disease are not considered, such as plasma levels of triglycerides and LDL, family history of early cardiovascular disease, family history of hypertension, BMI (overweight, obesity), abdominal obesity, eating habits, and level of physical activity. The cross-sectional design of the study is also a limiting factor, as the estimated risk of cardiovascular disease development over 10 years was assessed rather than the direct verification of events.

Another limiting factor was the combination of medium and high risk groups for statistical analysis, as the great advantage of scores is their discriminative power. In this study, on the one hand, patients in the medium risk group could have a similar evolution to that of the patients in the low risk group; on the other hand, associating them to the low risk group could underestimate their chance of developing cardiovascular disease.

The mean absolute risk of occurrence of a cardiovascular event over the next ten years in the studied sample was 9.5%, which is higher than the values reported in the literature for the Brazilian population. In a study of 329 executives in São Paulo, Rodrigues and Phillip17 found a low probability of occurrence of cardiovascular events over ten years (average risk of 5.7%). Similar values were also found in a study conducted in the state of Amazonas (average risk of 5.4 to 5.7%, depending on location)18.

Another study, involving 1,712 individuals aged between 30 and 59 years residing in Bambuí, state of Minas Gerais, also showed low cardiovascular risk (more than half of the population did not exceed the 5% risk)19. The data found in the present study population are in agreement with the mean values of cardiovascular risk described in populations submitted to liver transplantation - 7.9% in the study by Johnston et al.9 and 11.5% in the study by Neal et al.20, supporting the premise that these patients have higher risk of developing cardiovascular disease.

The mean risk found (9.5%) is very close to the value of 10% (considered intermediate risk); nearly half the studied population (46.1%) showed medium to high risk, and of these, approximately 30% were classified as high risk. Therefore, these results emphasize the need for intervention measures proposed in the last Brazilian guideline on dyslipidemia and atherosclerosis prevention16.

The level of physical activity and categorization of patients as sedentary, low active, and active were not associated with cardiovascular risk in this study. Although low levels of physical activity and a sedentary lifestyle are classic risk factors for cardiovascular disease16, it should be noted that the calculation of the daily physical activity level had limitations, as the time available for detailed descriptions of daily activities at the time of data collection was short. Furthermore, the calculation was made based on the activities performed by that patient at the time of the data collection, and thus, it may not reflect the entire period of time elapsed from transplantation (or since liver disease limited the daily activities and reduced the level of daily physical activities) to the date of evaluation.

In the present study, male gender, older age, and higher BMI at the time of evaluation were considered predictive factors for medium and high risk of cardiovascular events in the population undergoing liver transplantation. It is known that cardiovascular disease mortality is higher in males, when compared to females, at all circumstances and all age ranges, and that the occurrence of events increases progressively with age21. The higher incidence of cardiovascular disease in males compared to females of similar ages has been attributed not only to gender differences related to sexual hormones, but also to differences in cell and vascular tissue that mediate specific sexual responses22. Moreover, a higher score in the Framingham risk score is attributed to both older age and male sex. However, the permanence of these variables in the model would help to eliminate confounding factors.

In the studied population, BMI was the anthropometric measure most often related to higher incidence of cardiovascular events. The results showed that a higher BMI at the time of assessment tended to show statistical significance (p = 0.09) in the multivariate analysis as an independent factor for cardiovascular risk.

On the other hand, the removal of this variable would negatively impact the fit of the model and thus, it was kept in the analyses. The association between the degree of obesity and the incidence of cardiovascular events has been well described in the literature23-24.

It has been know for some time that weight gain after adulthood results in an increased risk of cardiovascular disease in both genders25. Overweight and obesity are also indicated in the population undergoing liver transplantation as related to cardiovascular risk6,11. The WC and WHR were associated with increased likelihood of developing cardiovascular events only in the univariate analysis. Although the BMI at the time of evaluation was the best predictor of cardiovascular risk, WC and WHR measure the amount of central adipose tissue, which is more metabolically active than peripheral fat tissue, thus implying in a higher risk factor for metabolic syndrome, insulin action resistance and cardiovascular disease in the general population26,27. A high BMI reflects a great mass of adipose tissue, which, especially when it is visceral, influences the regulation of adipokines.

Adiponectin is an anti-inflammatory adipokine (it antagonizes the development of atherosclerosis and vascular inflammation), which shows decreased serum concentrations in obese individuals. Serum concentrations of leptin, which controls food intake, are increased in these individuals influencing the energy balance and compromising the immune response.

The evidence suggests that leptin increases blood pressure and sympathetic nerve activity, stimulates the generation of reactive oxygen species, induces platelet aggregation, and promotes arterial thrombosis, being considered an independent risk factor for cardiovascular disease. In addition, resistin expression in adipocytes is reduced but it is high in macrophages and monocytes, suggesting an important role in inflammation. Resistin levels are elevated in obese individuals and, therefore, are linked with obesity-related insulin resistance. Resistin has a high atherogenic action by increasing the expression of intercellular adhesion molecules. Concomitantly, there is increased secretion of proinflammatory cytokines that collectively damage the endothelium, stimulating inflammatory/proliferative reaction in the vascular wall28.

In addition to increased BMI, patients classified as having medium/high risk had significantly higher triglycerides and glucose levels and lower HDL levels. These findings suggest that these patients have a higher prevalence of metabolic syndrome than low risk patients. Metabolic syndrome is described in approximately half of patients undergoing liver transplantation29, and has also been described as a risk factor for cardiovascular disease in this population30, as well as in the general population31. These results were expected, as triglycerides, glucose, and HDL are part of the Framingham score, either directly or indirectly.

The multiple linear regression analysis demonstrated that the use of cyclosporine, at the expense of the use of tacrolimus, was associated with greater percentage of risk of cardiovascular events. Other studies also showed this association32-33.

This fact can be explained by the influence of this drug on blood pressure, and cyclosporine is considered to be more hypertensive than tacrolimus6,20,32. Although these results are in agreement with literature data, it is important to note that, at the moment of the evaluation, few patients were taking cyclosporine (11.3%, n = 13), as the current immunosuppression protocol for transplants where the study was carried out is based on the use of tacrolimus.

Based on the results, it can be concluded that the risk of incidence of cardiovascular events over the next ten years in patients undergoing liver transplantation is higher than that of the general Brazilian population. These aspects indicate the need for greater attention of multidisciplinary teams involved in the care of these patients. These patients should be introduced early into lifestyle modification programs, especially male and older individuals.

 

REFERENCES

1. Orozco J, Vargas H. Liver transplantation: from child to MELD. Med Clin North Am. 2009;93(4):931-50.         [ Links ]

2. Laba M, Pszenny A, Gutowska D, Jonas M, Durlik M, Paczek L et al. Quality of life after liver transplantation--preliminary report. Ann Transplant. 2008;13(4):67-71.         [ Links ]

3. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transplant. 2004;10(7):886-97.         [ Links ]

4. Simo KA, Sereika S, Bitner N, Newton KN, Gerber DA. Medical epidemiology of patients surviving ten years after liver transplantation. Clin Transplant. 2010;25(3):360-7.         [ Links ]

5. Anastacio LR, Lima AS, Toulson Davisson Correia MI. Metabolic syndrome and its components after liver transplantation: incidence, prevalence, risk factors, and implications. Clin Nutr. 2010;29(2):175-9.         [ Links ]

6. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transplant. 2008;14(11):1648-54.         [ Links ]

7. Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int. 2010;30(7):948-57.         [ Links ]

8. Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transplant. 2006;12(3):394-401.         [ Links ]

9. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation. 2002;73(6):901-6.         [ Links ]

10. Mells G, Neuberger J. Long-term care of the liver allograft recipient. Semin Liver Dis. 2009;29(1):102-20.         [ Links ]

11. Aberg F, Jula A, Hockerstedt K, Isoniemi H. Cardiovascular risk profile of patients with acute liver failure after liver transplantation when compared with the general population. Transplantation. 2010;89(1):61-8.         [ Links ]

12. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9 Suppl):S498-504.         [ Links ]

13. World Health Organization W. Energy and protein requirements. Geneva: WHO; 1985.         [ Links ]

14. WHO. Obesity: preventing and managing the global epidemic. Genebra: World Health Organization; 1998.         [ Links ]

15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80.         [ Links ]

16. Sposito AC, Caramelli B, Fonseca FAH, Bertolami MC. IV Diretriz Brasileira Sobre Dislipidemias e Prevenção da Aterosclerose Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2007;8(Supl 1):1-19.         [ Links ]

17. Rodrigues TF, Philippi ST. Avaliação nutricional e risco cardiovascular em executivos submetidos a check-up. Rev Assoc Med Bras. 2008;54(4):322-7.         [ Links ]

18. Feio CM, Fonseca FA, Rego SS, Feio MN, Elias MC, Costa EA et al. Lipid profile and cardiovascular risk in two Amazonian populations. Arq Bras Cardiol. 2003;81(6):596-9, 592-5.         [ Links ]

19. Barreto SM, Passos VM, Cardoso AR, Lima-Costa MF. Quantifying the risk of coronary artery disease in a community: the Bambui project. Arq Bras Cardiol. 2003;81(6):556-61, 549-55.         [ Links ]

20. Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation. 2004;77(1):93-9.         [ Links ]

21. Farias N, Souza JM, Laurenti R, Alencar SM. Cardiovascular mortality by gender and age range in the city of Sao Paulo, Brazil: 1996 to 1998, and 2003 to 2005. Arq Bras Cardiol. 2009;93(5):498-505.         [ Links ]

22. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 2009;6(8):532-42.         [ Links ]

23. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097-105.         [ Links ]

24. Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008;52(1):39-48.         [ Links ]

25. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-77.         [ Links ]

26. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.         [ Links ]

27. Ashwell M, Gibson S. Waist to height ratio is a simple and effective obesity screening tool for cardiovascular risk factors: analysis of data from the British National Diet And Nutrition Survey of adults aged 19-64 years. Obes Facts. 2009;2(2):97-103.         [ Links ]

28. Marinou K, Tousoulis D, Antonopoulos AS, Stefanadi E, Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol. 2010;138(1):3-8.         [ Links ]

29. Anastácio LR, Ferreira LG, Ribeiro HS, Liboredo JC, Lima AS, Correia MITD. Metabolic syndrome after liver transplantation: prevalence and predictive factors. Nutrition. 2011;27(9):931-7.         [ Links ]

30. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007;13(8):1109-14.         [ Links ]

31. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93(2):136-41.         [ Links ]

32. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg. 1997;3(1):1-9.         [ Links ]

33. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg. 2002;183(5):595-9.         [ Links ]

 

 

Correspondence to:
Hélem de Sena Ribeiro
Av. Alfredo Balena, 110 - Sl. 208
30130-110 Belo Horizonte - MG, Brasil
helemsena@gmail.com

Submitted on: 10/24/2011
Approved on: 01/13/2012
Financial Support: Coordenação de Aperfeiçoamento Pessoal do Ensino Superior - CAPES - HSR is a MSc fellow and LRA is a PhD degree fellow. Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG - LGF is a PhD degree fellow. Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq - MITDC is a research fellow.
Conflict of interest: None.

 

 

Study conducted at Instituto Alfa de Gastroenterologia - Hospital das Clínicas da Universidade Federal de Minas Gerais Belo Horizonte, MG, Brazil